Videos

1 expert is featured in this series

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, shares his perspective on where subcutaneous amivantamab may fit in the treatment paradigm for previously treated, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), based on cohort 1 data from OrigAMI-4 and the agent's Breakthrough Therapy Designation.